R Squared’s Capricor Therapeutics CAPR Stock Holding History

R Squared’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30	Closed	-$414	–	498
2024 Q4	$414	Buy	+30	New	+$526	﹤0.01%	1543

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

R Squared's CAPR Position: Q1 2025 in Review

R Squared sold out of Capricor Therapeutics (CAPR) in Q1 2025, closing a stake of 30 shares — an estimated $414 sold.

R Squared first reported a position in CAPR in Q4 2024 and held it in 1 quarter. The position peaked at $414 in Q4 2024. 120 funds tracked by Wall St. Rank hold CAPR as of Q1 2025.

R Squared reported no remaining Capricor Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 30 Capricor Therapeutics shares in Q1 2025, an estimated $414.
R Squared first reported a position in Capricor Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Capricor Therapeutics position peaked at $414 in Q4 2024.
120 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.